Key result
Renin-angiotensin system inhibition after CABG was associated with a reduction in MACE (aHR 0.88; 95% CI 0.83-0.93; p<0.0001), both in patients with and without an indication for treatment.
Why the study?
RAS inhibitors are recommended post-CABG only for specific indications, leaving long-term utilization and outcomes in patients with and without indications uncharacterized.
Does renin-angiotensin system (RAS) inhibition reduce major adverse cardiovascular events in patients after isolated first-time coronary artery bypass grafting?
Cohort (n=28,782)
Yes
Does renin-angiotensin system (RAS) inhibition reduce major adverse cardiovascular events in patients after isolated first-time coronary artery bypass grafting?
Hazard Ratio: 0.88 (95% CI 0.83–0.93)
p-value: p=< 0.0001
RAS inhibition after CABG is associated with a significant reduction in major adverse cardiovascular events, even in patients without standard indications for the therapy.
No takes yet. Share an insight, caveat, or question.
Should not yet change post-CABG RAS inhibitor prescribing; supports benefit irrespective of indication and warrants RCTs.
Martinsson et al. (2021) conducted a cohort in Post-coronary artery bypass grafting (CABG) (n=28,782). Renin-angiotensin system (RAS) inhibitors vs. No RAS inhibitors was evaluated on Major adverse cardiovascular events (MACE), defined as all-cause mortality, stroke and/or myocardial infarction (aHR 0.88, 95% CI 0.83-0.93, p=< 0.0001). Renin-angiotensin system inhibition after CABG was associated with a reduction in MACE (aHR 0.88; 95% CI 0.83-0.93; p<0.0001), both in patients with and without an indication for treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: